G-CSF in Stroke Patients with Vascular Disease
Author Information
Author(s): Agnes Floel, Tobias Warnecke, Thomas Duning, Yvonne Lating, Jan Uhlenbrock, Armin Schneider, Gerhard Vogt, Rico Laage, Winfried Koch, Stefan Knecht, Wolf-Rüdiger Schäbitz
Primary Institution: Charité-Universitätsmedizin Berlin
Hypothesis
Can G-CSF promote recovery in chronic stroke patients with concomitant vascular disease?
Conclusion
The study shows that G-CSF is safe and reasonably well tolerated in chronic stroke patients, but did not demonstrate significant efficacy in improving hand motor function.
Supporting Evidence
- G-CSF was well tolerated with mostly mild to moderate adverse events.
- Leukocyte counts increased significantly during treatment but returned to baseline after cessation.
- No significant effect on hand motor function was detected between G-CSF and placebo groups.
Takeaway
This study tested a drug called G-CSF to see if it helps people recover after a stroke, but while it was safe to use, it didn't really help them get better.
Methodology
41 chronic stroke patients were randomly assigned to receive either G-CSF or placebo for 10 days, and their safety and efficacy were assessed.
Potential Biases
Potential bias due to the small sample size and the nature of the treatment assignment.
Limitations
The study was underpowered to detect significant effects due to a small sample size and a heterogeneous patient population.
Participant Demographics
41 individuals aged 48-85 years, with a mean age of 68, including 13 women.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website